Press Releases Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:52 2024-12-05 am EST			5-day change	1st Jan Change
256.30 ^CHF	+1.02%		+0.95%	+4.83%

Dec. 05	Swiss Stocks Close Flat as Local Unemployment Rate Edges Higher	MT
Dec. 05	Roche: FDA accepts Columvi's review in lymphoma	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Dec. 05	BU
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results	Nov. 26	BU
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024	Nov. 05	BU
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer	Oct. 30	BU
Roche : Nine-month 2024 Presentation (irp231024 a)	Oct. 23	PU
Roche : Nine-month 2024 Presentation with appendix (irp231024)	Oct. 23	PU
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study	Oct. 18	BU
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate	Oct. 14	BU
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	Oct. 10	BU
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis	Sep. 26	BU
Invitation to Roche's 3rd Quarter Sales 2024 Presentation	Sep. 24	AQ
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses	Sep. 19	BU
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis	Sep. 13	BU
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy	Sep. 12	BU
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions	Jul. 18	BU
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study	Jul. 17	BU
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity	Jul. 17	BU
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)	Jul. 08	BU
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss	Jul. 05	BU
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer	Jul. 04	BU
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Jun. 15	BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk	Jun. 07	BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	May. 29	BU
Roche and Hitachi High-Tech extend their long-standing partnership	May. 28	AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	May. 21	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : Slight beat in the Q3; full-year outlook retained

October 23, 2024 at 12:01 pm EDT

Roche CEO 'Very Confident' on Outlook, Momentum

October 23, 2024 at 08:38 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST